Skip to the main content.
Facebook Instagram Linkedin X YouTube Medium

megamenu-services

 

Turn Vision into Velocity with the Innovation CRO

Traditional CROs fragment device development with costly hand-offs and learning curves. Veranex unites the essential disciplines for medical device & diagnostic development under one roof from sketch to evidence-generation to market launch.

All connected. All aligned. All accelerating your path to market—delivering breakthrough devices and diagnostics that improve patient lives sooner.

Explore our Services

megamenu-solutions-expertise

 

Outcome-Driven Solutions for Medtech Challenges

Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.

Purpose-built solutions. Proven results. User & Patient-centered innovation.

 

Solutions

Expertise

megamenu-company-2

 

Purpose-Built for Breakthroughs

Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity.  Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.  

We are the Innovation CRO.

Legacy of excellence. Proven execution. Patient impact accelerated.

 

Explore our Company

Veranex Presents Study Results at the National Kidney Foundation Spring Clinical Meeting

admin.veranex : Mar 24, 2025 10:22:49 PM

Commercialization

Dr. Manasi Datar and colleagues used conjoint analysis to estimate preferences regarding kidney disease testing from 401 PCPs via a web survey. Hypothetical patient profiles created using clinical parameters demonstrated the clinical utility of a novel kidney diagnostic used to risk-stratify patients based on the risk of kidney function decline.

Read the Article

Study by Veranex and Proteomics International Demonstrates Clinical Utility of Prognostic Test for Type 2 Diabetes Patients

admin.veranex : Mar 24, 2025 10:23:07 PM

By conducting a clinical utility study for Proteomics International’s PromarkerD (a blood-based test that predicts the risk of kidney...

Commercialization
Read More

Leveraging Medtech Innovation in Clinical Trials

admin.veranex : Mar 24, 2025 10:23:11 PM

Rebecca Ford, Director of Program Management, discusses how to Leverage medical technology and innovation in clinical trials to drive medication...

Read More

Recent Study Co-authored by Veranex Staff Highlights Cost-effectiveness of Home Non-invasive Ventilation in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United Kingdom

admin.veranex : Mar 24, 2025 10:23:08 PM

By developing a cost-effectiveness model and associated manuscript for home non-invasive ventilation in patients with persistent hypercapnia after...

Commercialization
Read More